RxDoctor Payments Data

Kevin Dean, OD

Optometrist · Davie, FLNPI 1568199727

Payments from drug & device makers

$1,496in general payments, 2019–2025

Across 32 payments — averaging $46.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$411
  • Biotissue Holdings Inc.$269
  • Optos, Inc.$175
  • Alcon$162
  • Bausch & Lomb Americas Inc.$125
  • Amgen$125
  • plus $230 from 7 others

What the payments were for

  • Food & beverage$1,496100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,496 in reported general payments places this provider in the 60th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$34,804
Medicare patients
142
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine23$19,043
XiidraLifitegrast18$13,625
EysuvisLoteprednol Etabonate23$11,334
CombiganBrimonidine Tartrate/Timolol33$10,798
RocklatanNetarsudil Mesylat/Latanoprost28$9,989
LumiganBimatoprost20$9,780
VyzultaLatanoprostene Bunod18$7,385
SimbrinzaBrinzolamide/Brimonidine Tart33$7,270
Prednisolone Acetate48$3,005
Brimonidine Tartrate50$2,987
Dorzolamide Hcl45$885
Latanoprost123$664
Timolol Maleate34$561
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat38$544
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$411$39,62176 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$125$21,01036 claims
AlconSimbrinza$162$7,27033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Davie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →